These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 24668346)
1. Structural and redox requirements for the action of anti-diabetic vanadium compounds. Yoshikawa Y; Sakurai H; Crans DC; Micera G; Garribba E Dalton Trans; 2014 May; 43(19):6965-72. PubMed ID: 24668346 [TBL] [Abstract][Full Text] [Related]
2. Complex formation of vanadium(IV) with 1,3,5-triamino-1,3,5-trideoxy-cis-inositol and related ligands. Morgenstern B; Steinhauser S; Hegetschweiler K; Garribba E; Micera G; Sanna D; Nagy L Inorg Chem; 2004 May; 43(10):3116-26. PubMed ID: 15132617 [TBL] [Abstract][Full Text] [Related]
3. V(IV)O versus V(IV) complex formation by tridentate (O, N(arom), O) ligands: prediction of geometry, EPR 51V hyperfine coupling constants, and UV-Vis spectra. Pisano L; Várnagy K; Timári S; Hegetschweiler K; Micera G; Garribba E Inorg Chem; 2013 May; 52(9):5260-72. PubMed ID: 23581472 [TBL] [Abstract][Full Text] [Related]
4. Salicylamide and salicylglycine oxidovanadium complexes with insulin-mimetic properties. Nilsson J; Shteinman AA; Degerman E; Enyedy EA; Kiss T; Behrens U; Rehder D; Nordlander E J Inorg Biochem; 2011 Dec; 105(12):1795-800. PubMed ID: 22056176 [TBL] [Abstract][Full Text] [Related]
5. Aqueous chemistry of the vanadium(III) (V(III)) and the V(III)-dipicolinate systems and a comparison of the effect of three oxidation states of vanadium compounds on diabetic hyperglycemia in rats. Buglyó P; Crans DC; Nagy EM; Lindo RL; Yang L; Smee JJ; Jin W; Chi LH; Godzala Iii ME; Willsky GR Inorg Chem; 2005 Jul; 44(15):5416-27. PubMed ID: 16022540 [TBL] [Abstract][Full Text] [Related]
6. Correlation of insulin-enhancing properties of vanadium-dipicolinate complexes in model membrane systems: phospholipid langmuir monolayers and AOT reverse micelles. Sostarecz AG; Gaidamauskas E; Distin S; Bonetti SJ; Levinger NE; Crans DC Chemistry; 2014 Apr; 20(17):5149-59. PubMed ID: 24615733 [TBL] [Abstract][Full Text] [Related]
7. Formation in aqueous solution of a non-oxido V(IV) complex with VN6 coordination. Potentiometric, ESI-MS, spectroscopic and computational characterization. Lodyga-Chruscinska E; Szebesczyk A; Sanna D; Hegetschweiler K; Micera G; Garribba E Dalton Trans; 2013 Oct; 42(37):13404-16. PubMed ID: 23893076 [TBL] [Abstract][Full Text] [Related]
8. Bis(allixinato)oxovanadium(IV) complex is a potent antidiabetic agent: studies on structure-activity relationship for a series of hydroxypyrone-vanadium complexes. Adachi Y; Yoshida J; Kodera Y; Katoh A; Takada J; Sakurai H J Med Chem; 2006 Jun; 49(11):3251-6. PubMed ID: 16722643 [TBL] [Abstract][Full Text] [Related]
14. Anti-diabetic effects of vanadium(III, IV, V)-chlorodipicolinate complexes in streptozotocin-induced diabetic rats. Li M; Ding W; Smee JJ; Baruah B; Willsky GR; Crans DC Biometals; 2009 Dec; 22(6):895-905. PubMed ID: 19404749 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and characterization of novel binary V(V)-Schiff base materials linked with insulin-mimetic vanadium-induced differentiation of 3T3-L1 fibroblasts to adipocytes. Structure-function correlations at the molecular level. Halevas E; Tsave O; Yavropoulou MP; Hatzidimitriou A; Yovos JG; Psycharis V; Gabriel C; Salifoglou A J Inorg Biochem; 2015 Jun; 147():99-115. PubMed ID: 25920352 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and pharmacological evaluation of novel vanadium-containing complexes as antidiabetic agents. Fedorova EV; Buryakina AV; Zakharov AV; Filimonov DA; Lagunin AA; Poroikov VV PLoS One; 2014; 9(7):e100386. PubMed ID: 25057899 [TBL] [Abstract][Full Text] [Related]
17. pH-metric chemical speciation modeling and studies of in vitro antidiabetic effects of bis[(imidazolyl)carboxylato]oxidovanadium(IV) complexes. Gundhla IZ; Walmsley RS; Ugirinema V; Mnonopi NO; Hosten E; Betz R; Frost CL; Tshentu ZR J Inorg Biochem; 2015 Apr; 145():11-8. PubMed ID: 25594947 [TBL] [Abstract][Full Text] [Related]
18. Characterization and biotransformation in the plasma and red blood cells of V(IV)O(2+) complexes formed by ceftriaxone. Sanna D; Fabbri D; Serra M; Buglyó P; Bíró L; Ugone V; Micera G; Garribba E J Inorg Biochem; 2015 Jun; 147():71-84. PubMed ID: 25601642 [TBL] [Abstract][Full Text] [Related]
19. Investigation of the insulin-like properties of zinc(II) complexes of 3-hydroxy-4-pyridinones: identification of a compound with glucose lowering effect in STZ-induced type I diabetic animals. Moniz T; Amorim MJ; Ferreira R; Nunes A; Silva A; Queirós C; Leite A; Gameiro P; Sarmento B; Remião F; Yoshikawa Y; Sakurai H; Rangel M J Inorg Biochem; 2011 Dec; 105(12):1675-82. PubMed ID: 22088976 [TBL] [Abstract][Full Text] [Related]
20. Possible mode of action for insulinomimetic activity of vanadyl(IV) compounds in adipocytes. Kawabe K; Yoshikawa Y; Adachi Y; Sakurai H Life Sci; 2006 May; 78(24):2860-6. PubMed ID: 16337244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]